Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be male or female of any race, at least 18 years of age~* Have provided written informed consent~* Have a reported history of dry eye syndrome~* Have a history of use or desire to use eye drops for dry eye~Exclusion Criteria:~* Have any clinically significant eye findings that require therapeutic treatment or may interfere with study parameters~* Have previously had LASIK surgery within the last 12 months~* Have used Restasis® within 30 days of Visit 1~* Be a woman who is pregnant, nursing or planning a pregnancy~* Be unwilling to submit a urine pregnancy test if of childbearing potential~* Have a known allergy and/or sensitivity to the test article or its components, including the preservative benzalkonium chloride~* Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1~* Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose SkQ1 (Type: EXPERIMENTAL): Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
- High Dose SkQ1 (Type: EXPERIMENTAL): Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
- Placebo (vehicle) (Type: PLACEBO_COMPARATOR): Drug: Placebo (vehicle) ophthalmic solution administered twice daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).